盐酸氨溴索不同给药途径对慢性阻塞性肺疾病急性发作期患者的疗效比较

目的对比盐酸氨溴索氧气驱动雾化吸入与静脉用药治疗慢性阻塞性肺疾病急性发作期（AECOPD）的疗效。方法将医院2011年1月至2013年1月住院的120例患者随机分为两组,各60例。两组均给予常规对症治疗,观察组加用盐酸氨溴索注射液15 mg,每日2次氧驱动雾化吸入,对照组将盐酸氨溴索注射液加入0.9%氯化钠注射液100 mL静脉滴注,每日2次。结果观察组总有效率为93.33%,显著高于对照组的68.33%（P〈0.05）。观察组患者咳嗽发作终止平均时间、肺部罗音消失时间、住院时间均显著短于对照组（P〈0.05）。观察组无明显不良反应发生,对照组有11例（18.33%）患者出现恶心、头痛、腹泻、皮疹等不良反应。结论盐酸氨溴索氧气驱动雾化吸入辅助治疗AECOPD的疗效确切且优于静脉用药,操作简便,未见明显不良反应,值得临床推广。

Comparison of Effects of Different Administration Routes of Ambroxol Hydrochloride in Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Objective To compare the effects between oxygen- driven aerosol inhalation and intravenous ambroxol hydrochloride in treating acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods 120 patients with AECOPD admitted to our hospital from January 2011 to January 2013 were randomly divided into the observation group and the control group, 60 cases in each group. Both groups were treated with conventional symptomatic treatment. On this basis the observation group was added with ambroxol hydrochloride 15 mg per time by oxygen-driven aerosol inhalation, twice daily, while the control group was intravenously dipped by am- broxol hydrochloride plus 0. 9% sodium chloride injection 100 mL, twice daily. The effects and adverse reactions were compared between the two groups. Results The total effective rate was 93.33% in the observation group, which was significantly higher than 68.33% in the control group（ P 〈 0.05）. The average time of cough stopping, disappearing time of pulmonary rales and hospitalization duration in the observation group were significantly lower than those in the control group（P〈0. 05）. No obvious adverse reactions occurred in the observation group; ll cases（18.33% ） in the control group appeared the adverse reactions of nausea, headache, diarrhea and skin rashes. Conclusion Ambroxol hydrochloride by oxygen- driven aerosol inhalation has definite effect for treating AECOPD, and superior to the intravenous medication and simple to operate without obvious adverse reactions, which is worty of clinical promotion.